What You Should Know:
– Amwell, who has collaborated with Biobeat, and will integrate Biobeat’s AI-powered wearable remote patient monitoring solutions into its Converge virtual care platform.
– The integration will allow clinicians using Amwell’s Converge platform to continuously monitor patient vitals and receive deterioration alerts directly to their mobile phones via Biobeat’s AI-powered, automated real-time early warning score system.
– Amwell powers telehealth solutions for more than 2,000 hospitals and over 55 health plan partners with over 36,000 employers, covering over 80 million lives.
– Biobeat’s wearable patient monitoring devices can detect 15 cardio-pulmonary vital sign measurements (first-ever FDA Cleared cuffless blood pressure, blood saturation, heart rate, respiratory rate, ECG ratings, and more), providing healthcare providers with 128 data points per second and more than 150 million individual data points per patient each day.
– The technology is used by healthcare facilities (including hospitals, nursing homes) across the globe, in addition to 10+ major pharmaceutical companies and CROs, including Amgen, Bayer, and AstraZeneca.
